BridgeBio PharmaBBIO
BBIO
About: BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Employees: 556
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
317% more call options, than puts
Call options by funds: $288M | Put options by funds: $68.9M
43% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 72
8% more funds holding in top 10
Funds holding in top 10: 12 [Q2] → 13 (+1) [Q3]
3% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 39
0% more funds holding
Funds holding: 248 [Q2] → 249 (+1) [Q3]
2% less capital invested
Capital invested by funds: $4.46B [Q2] → $4.36B (-$100M) [Q3]
3.01% less ownership
Funds ownership: 94.19% [Q2] → 91.18% (-3.01%) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$45
59%
upside
Avg. target
$48
68%
upside
High target
$50
76%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Evercore ISI Group Cory Kasimov 27% 1-year accuracy 4 / 15 met price target | 76%upside $50 | Outperform Maintained | 23 Dec 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 130 / 313 met price target | 73%upside $49 | Buy Reiterated | 16 Dec 2024 |
Scotiabank Greg Harrison 33% 1-year accuracy 9 / 27 met price target | 69%upside $48 | Sector Outperform Maintained | 25 Nov 2024 |
B of A Securities Geoff Meacham 36% 1-year accuracy 9 / 25 met price target | 59%upside $45 | Buy Maintained | 25 Nov 2024 |
Leerink Partners Mani Foroohar 25% 1-year accuracy 4 / 16 met price target | 62%upside $46 | Outperform Maintained | 17 Oct 2024 |
Financial journalist opinion
Based on 3 articles about BBIO published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for acoramidis for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered near-complete (≥90%) transthyretin (TTR) stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. In the Phase 3 study ATTRibute-CM, acoramidis showed clear benefits on cardiovascular outcomes.
Neutral
GlobeNewsWire
3 weeks ago
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology
SANTA CRUZ, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today that BridgeBio Pharma, Inc. (Nasdaq: BBIO), has exercised its option to license macrocyclic peptide candidates discovered using UNP's AI-enabled massively parallel chemistry platform.
Positive
Zacks Investment Research
4 weeks ago
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
Positive
Investors Business Daily
1 month ago
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.
Positive
Benzinga
1 month ago
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
On Friday, the FDA approved BridgeBio Pharma, Inc.'s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.
Positive
Seeking Alpha
1 month ago
BridgeBio: Next Chapter Begins After Attruby Approval
BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also triggers a $500 million milestone payment to BridgeBio under the royalty-backed deal it signed earlier this year and removes a regulatory and funding overhang on the stock.
Positive
Reuters
1 month ago
US FDA approves BridgeBio's drug for rare heart condition
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer's blockbuster Vyndaqel.
Neutral
GlobeNewsWire
1 month ago
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes
Positive
Benzinga
1 month ago
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
On Monday, BridgeBio Pharma, Inc. BBIO presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions.
Neutral
GlobeNewsWire
1 month ago
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension
Charts implemented using Lightweight Charts™